Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia

被引:20
作者
Horn, D.
Neofytos, D.
Fishman, J.
Steinbach, W.
Anaisie, E.
Marr, K. A.
Pfaller, M.
Olyaei, A.
机构
[1] Thomas Jefferson Univ Hosp, Div Infect Dis, Philadelphia, PA 19107 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA
[3] Duke Univ, Med Ctr, Div Pediat Infect Dis, Durham, NC 27710 USA
[4] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Div Support Care, Little Rock, AR 72205 USA
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98119 USA
[6] Univ Iowa Hlth Care, Dept Pathol, Iowa City, IA 52242 USA
[7] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97239 USA
[8] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA
关键词
D O I
10.1007/s10096-007-0383-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Candidemia is an increasing complication of the care of complex patients. Adherence to Infectious Diseases Society of America (IDSA) guidelines for the treatment of candidemia was investigated to assess the impact of compliance on outcomes of therapy. Data on the epidemiology, diagnosis, and treatment of patients with invasive fungal infections (IFIs) was extracted from the PATH Alliance registry, a prospective, multicenter, observational database of invasive fungal infections. Patients with proven candidemia were evaluated for adherence to the IDSA guidelines in terms of choice, dosage, and duration of antifungal therapy. Removal of central venous catheters and time to treatment initiation were assessed. Four-week survival data were compared. Of the 418 patients with candidemia who were included in the study, 361 patients with the necessary data sets were identified, of whom 262 (72.6%) were treated within the IDSA guidelines for the treatment of candidemia (IDSA group); the remaining 99 (27.4%) patients received treatment different from the guidelines (non-IDSA group). Kaplan-Meier (KM) survival analysis for patients in the IDSA and non-IDSA group showed mortality rates of 21.9 and 13.6%, respectively; the difference between the two groups was not statistically significant (P=0.093). Following the exclusion of patients requiring mechanical ventilation or acute cardiac support, the modified survival KM curves were similar between the two groups. Significantly more patients in the IDSA group required mechanical ventilation and tunneled central catheters, had a concomitant IFI, and received caspofungin. The duration of treatment and inappropriate dosing did not appear to have had a significant impact on survival. Most of the deviations from IDSA guidelines were due to the inappropriate duration and dosing of therapy. No significant difference in mortality was noted between the IDSA and non-IDSA groups. The basis of these differences merit further study.
引用
收藏
页码:907 / 914
页数:8
相关论文
共 15 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]   Nosocomial bloodstream infections in United States hospitals: A three-year analysis [J].
Edmond, MB ;
Wallace, SE ;
McClish, DK ;
Pfaller, MA ;
Jones, RN ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :239-244
[3]   Attributable mortality of nosocomial candidemia, revisited [J].
Gudlaugsson, O ;
Gillespie, S ;
Lee, K ;
Berg, JV ;
Hu, JF ;
Messer, S ;
Herwaldt, L ;
Pfaller, M ;
Diekema, D .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1172-1177
[4]   Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial [J].
Kullberg, BJ ;
Sobel, JD ;
Ruhnke, M ;
Pappas, PG ;
Viscoli, C ;
Rex, JH ;
Cleary, JD ;
Rubinstein, E ;
Church, LWP ;
Brown, JM ;
Schlamm, HT ;
Oborska, IT ;
Hilton, F ;
Hodges, MR .
LANCET, 2005, 366 (9495) :1435-1442
[5]  
Marr Kieren A, 2004, Oncology (Williston Park), V18, P9
[6]   Comparison of caspofungin and amphotericin B for invasive candidiasis. [J].
Mora-Duarte, J ;
Betts, R ;
Rotstein, C ;
Colombo, AL ;
Thompson-Moya, L ;
Smietana, J ;
Lupinacci, R ;
Sable, C ;
Kartsonis, N ;
Perfect, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2020-2029
[7]   Guidelines for treatment of candidiasis [J].
Pappas, PG ;
Rex, JH ;
Sobel, JD ;
Filler, SG ;
Dismukes, WE ;
Walsh, TJ ;
Edwards, JE .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :161-189
[8]   Initial management of candidemia at an academic medical center: Evaluation of the IDSA guidelines [J].
Patel, M ;
Kunz, DF ;
Trivedi, VM ;
Jones, MG ;
Moser, SA ;
Baddley, JW .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 52 (01) :29-34
[9]  
*PFIZ, 2006, ER INJ
[10]  
REBOLI A, 2005, 45 INT C ANT AG CHEM